Morgan Stanley analyst Michael Ulz maintained a Buy rating on Silence Therapeutics (SLN – Research Report) today and set a price target of $49.00. The company’s shares closed last Friday at $17.99.
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Silence Therapeutics (SLN – Research Report) and Monopar Therapeutics Inc (MNPR – Research Report).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback